Rare and large copy number variants (CNVs) around known genomic 'hotspots' are strongly 3 implicated in epilepsy etiology. But it remains unclear whether the observed associations are 4 specific to an epilepsy phenotype, and if additional risk signal can be found outside hotspots. 5
Introduction 1 2
Characterized by recurrent and unprovoked seizures, epilepsy is the third most common 3 neurological disorder, affecting roughly 65 million people worldwide 1 . The cause of epilepsy 4 is unknown in many patients and can be the result of a variety of insults that perturb brain 5 function. Along with acquired causes such as trauma, infectious diseases and autoimmune 6 diseases, genetic variants play a major role in the disease etiology 2 . To date, approximately 7 100 genes have been associated with epilepsy 2,3 . 8 9
The clinical representation of epilepsy is heterogeneous and subtype classification can be 10 challenging. The epilepsies can be grouped into four major phenotypes 4 : (1) genetic 11 generalized epilepsies (GGE), (2) focal epilepsies with non-acquired focal epilepsies (NAFE) 12 and lesional focal epilepsies (LFE), (3) developmental and epileptic encephalopathies 13 (DEE), and (4) unclassified epilepsies (UE). Among all epilepsy phenotypes, the DEE group 14 has the poorest prognosis 4, 5 . 15
16
In the last decade, many genetic studies have established that single nucleotide variants can 17 confer risk or cause epilepsy 2,6 . Disease causing de novo variants have been reported in 18 patients with DEE 7 and seizure susceptibility variants have been identified in GGE (for a 19 review see 8 . Focal epilepsies have been associated with germline, somatic and mosaic 20 pathogenic variants in e.g. PCDH19 9 , LGI1, SCN1A and CHRNA4 (for a review see Helbig 21 et al., 2016 10 ) and especially in genes associated with the mechanistic target of rapamycin 22 (mTOR) pathway 11, 12 . 23 24 Additionally, rare copy number variants (CNVs) are strongly implicated in the etiology of 25 epilepsy. Around four to eight percent of DEE patients carry pathogenic CNVs 13, 14 and CNVs 26 at genomic hotspots such as 15q13.3, 15q11.2, 16p11.2, 16p13.11 and 22q11.2 have been 27 associated with GGE [15] [16] [17] [18] [19] [20] [21] [22] . Rare genic CNVs were found in ~10% of GGE patients 13,18,23 and 28 3 CNVs greater than one megabase (Mb) were significantly enriched in patients compared to 1 controls 13, 14, 17, 24 . Deletions at 15q13.3, 15q11.2 and 16p13.11 are rarely seen in patients with 2 DEE, highlighting the notion that the major phenotypes of epilepsy have different genetic 3 architectures 25 . Non-recurrent deletions in RBFOX1 have been additionally found in patients 4 with focal epilepsies 26 and the 16p13.11 deletion was found in a study including GGE, 5 NAFE, and LFE patients combined 14 . However, no significant CNV association has been 6 identified to date with NAFE 22 and the role of CNVs in LFE has not been studied at large 7 scale. 8 9 To date, all of the current epilepsy CNV associations have been identified through candidate 10 loci screens, as genome-wide scans were under-powered to confirm significant genetic 11 associations of low frequency CNVs (<1%) with epilepsy. In addition, the vast majority of 12 CNV association studies have focused on deletions and not duplications. Lastly, no large-13 scale study uniformly processed or analyzed several types of epilepsy with the same 14 genotyping platform and analysis protocol, which would enable robust comparisons across 15 epilepsy phenotypes. 16 17 Here, we performed a large genome-wide analysis and the first CNV breakpoint association 18 analysis of both deletions and duplications in five different epilepsy phenotypes (n=11,246 19 cases and 7,318 controls), to decipher epilepsy phenotype-specific patterns as well as to 20 discover novel epilepsy-associated CNV loci. 21 Patients with an UE diagnosis did not fulfill criteria for any of the aforementioned epilepsy 8 phenotypes due to absence of critical data or conflicting data and are therefore under review 9 or were labeled excluded. Samples selected for this study were all genotyped on the GSA-MD v1.0 (Illumina, San 1 Diego, CA, USA) in separate batches. A total of 688,032 markers were used for quality 2 control (QC). 3
Genotype Sample QC: 4
To correct for population stratification, we performed an initial round of QC based on SNP 5 genotype data for 13,420 epilepsy cases and 12,857 controls. Samples with a call rate < 6 0.96 or discordant sex status were excluded. We filtered autosomal SNPs for low genotyping 7 rate (> 0.98), case-control difference in minor-allele frequency (> 0.05), and deviation from 8
Hardy-Weinberg equilibrium (HWE, p-value <= 0.001) before pruning SNPs for linkage 9 disequilibrium (--indep-pairwise 200 100 0.2) using PLINK v1.9 27 in order to perform 10 Principal Component Analysis (PCA) to assess for population stratification. Samples with 11 non-European ancestry were excluded based on visual clustering of the PCA. 12
CNV Calling: 13
We focused only on autosomal CNVs due to higher quality of CNV calls from nonsex 14 chromosomes 28 . We created GC wave-adjusted LRR intensity files for all samples using 15 PennCNV, and employed PennCNV's CNV calling algorithms 29 to detect CNVs in our 16 dataset. We generated a custom population B-allele frequency file before calling CNVs. 17
Adjacent CNV calls were merged if the number of intervening markers between them was 18 less than 20% of the total number when both segments were combined. 19 20
Intensity Sample QC: 21
Intensity-based QC was conducted to remove samples with low quality data based on the 22 following empirically defined thresholds across three different metrics: Thresholds for (1) 23 waviness factor, (2) Log-R ratio standard deviation, and (3) B-allele frequency drift were 24 calculated by taking the median +3x SD to determine outlying samples as performed in 25
Huang et al. 30 . Following intensity-based QC, all samples had an Log-R ratio standard 26 7 deviation of < 0.25, absolute value of waviness factor < 0.04, and a B-allele frequency drift < 1 0.007. 2 3 CNV-load Sample QC: 4
We performed a final round of sample QC by removing additional samples with excessively 5 high CNV load based on the total number of CNV calls (>100). This threshold was 6 determined empirically by visual inspection of distributions across all datasets combined. 7
Our final dataset after sample QC compromised 18,564 samples: 11,246 epilepsy cases and 8 7,318 controls (DEE = 1,315; GGE = 3,637; LFE = 1,267; NAFE = 4,520; UE = 507). 9
10 Call Filtering and Delineation of Rare CNVs: 11 CNV calls were removed from the dataset if they spanned less than 20 markers, were less 12 than 20Kb in length, had a SNP density < 0.0001 (amount of markers/length of CNV) or 13 overlapped by more than 0.5 of their total length with regions known to generate artifacts in 14 SNP-based detection of CNVs 31 . This included immunoglobulin domain regions, telomeric 15 regions (defined as 500Kb from the chromosome ends), and centromeric regions 16 (coordinates were provided by PennCNV for hg19). Further, we excluded CNVs overlapping 17 > 80% of regions known to be recurrent copy number variations in the general population 18 (11,732 CNVs from http://dgv.tcag.ca/dgv/app/home) for a part of the analyses (see "CNV 19 Burden Analysis"). Additionally, all CNV calls spanning more than 20 markers and equal to 20 or more than 1Mb in length were included in the analysis even if the SNP density was < 21 0.0001 30, 31 . 22
23
We assigned all CNV calls a specific frequency count using PLINK v.1.07 32 , with the option -24 -cnv-freq-method2 0.5. Here, the frequency count of an individual CNV is determined as 1 + 25 the total number of CNVs overlap by at least 50% of its total length (in bp), irrespective of 26 CNV type. We then filtered our callset for rare CNVs with MAF < 1% (a frequency of 186 or 27 lower across 18,564 samples). 28 8 1 After CNV quality control, 12,765 of 18,564 (7,748 cases and 5,017 controls) QC-passed 2 individuals had one or more rare CNVs. 3 4 CNV Annotation: 5
CNVs were annotated for gene content and recurrent deletion hotspots for epilepsy and 6 neurodevelopmental disorders (NDD) with various annotation files including gene name and 7 the corresponding coordinates in hg19 assembly using in-house perl scripts (available on 8 request). We annotated 89 genes that were previously associated with epilepsy 2,3 , 93 genes 9 associated with NDD 33 , 2,680 genes intolerant for protein truncating variants defined as pLI 10 > 0.95 34 (probability of loss-of-function intolerance [pLI] score > 0.95), >28,000 annotated 11 regions from UCSC refseq genes, eight recurrent hotspot deletion regions for epilepsy and 12 six recurrent hotspot regions for NDD 35 . We only considered a CNV as "coding" if it 13 overlapped 80% of a gene 36 . We considered all other CNVs as "non-genic". 14
15
Cytogenic testing is well-established for diagnostic evaluation of patients with 16 neurodevelopmental disorders including epilepsies. It is generally established that large 17 deletions, deletions intersecting haploinsufficient genes, and large duplications are 18 considered as likely pathogenic for epilepsy 37 . Therefore, we considered a CNV as "likely 19 pathogenic" as defined by ACMG guidelines 38 , i.e. if its length exceeded 2Mb, it overlapped 20 a known hotspot region for epilepsy, a gene with pLI > 0.95, or a known epilepsy-associated 21 gene. 22
23

CNV Burden Analysis: 24
We measured CNV burden for all five epilepsy phenotypes using three separate categories 25 to evaluate relative contribution on epilepsy type risk: (1) the total length of all rare CNVs 26 within an individual (CNV length), (2) the carrier status of rare CNVs intersecting genes and 27 9 neurodevelopmental or epilepsy associated CNVs hotspot regions, and (3) the carrier status 1 of rare likely pathogenic CNVs. For length and CNV burden in different gene and hotspot 2 lists, deletions and duplications were analyzed separately. For likely pathogenic CNV burden 3 duplications and deletions were analyzed according to the definition of "likely pathogenic" 4 CNVs mentioned before. To assess for a CNV burden difference between epilepsy cases 5 and controls, we fitted a logistic binomial (for hotspot regions including CNVs from the 6 general population) or Poisson (for gene lists and likely pathogenic CNV burden excluding 7
CNVs from the general population) regression model using the "glm" function of the stats 8 package (https://github.com/SurajGupta/r-source/tree/master/src/library/stats/R) in R for 9 common and rare CNVs respectively 30 : 10 y ~ sex + CNV burden 11
where 'y' is a dichotomous outcome variable (epilepsy type = 1, control = 0); 'sex' is used as 12 a covariate and 'CNV burden' represents one of the categories mentioned above. For all 13 burden analyses, ORs, 95% confidence intervals (CIs), and significance were calculated. 14 ORs were calculated by taking the exponential of the logistic regression coefficient. ORs 15 above one indicate an increased risk for the specific epilepsy type per unit of CNV burden. 16
Significance threshold was corrected for multiple testing using Bonferroni correction. 17
Bonferroni multiple-testing threshold for significance was calculated combined for all 18 epilepsy phenotypes and CNV types for all three categories ((1) CNV length burden p < 19 1.6e-3; (2) genome-wide burden p < 8.33e-4; (3) likely pathogenic CNV burden p < 0.01). 20
21
Regression of Potential Confounds on Case-Control Ascertainment: 22
It is important to ensure that any bias in gender and ancestry does not drive spurious 23 associations with epilepsy. To ensure the robustness of the analysis, CNV burden analyses 24 included potential confounding variables as covariates in a logistic regression framework. 25
Due to the number of tests run at breakpoint level association, we employed a step-wise 26 logistic regression approach to allow for the inclusion of covariates in our case-control 27 association, as previously described in Marshall and Howrigan et al. 31 , which we term the 28 10 epilepsy residual phenotype. Covariates included sex for burden and breakpoint association 1 analysis and the first ten ancestry principal components for breakpoint association analysis. 2 3 To calculate the epilepsy residual phenotype, we first fitted a logistic regression model of 4 covariates to affection status, and then extracted the Pearson residual values for use in a 5 quantitative association design for downstream analyses. Residual phenotype values in 6 cases are all above zero, and controls below zero, and are plotted against overall Kb burden 7
in Figure S1 . 8 9
CNV Breakpoint Level Association: 10
The CNV breakpoint level association was performed by quantifying the frequencies of case 11 and control CNV carriers at all unique CNV breakpoint locations (i.e., the SNP probe defining 12 the start and end of the CNV segment); the full set of CNV breakpoints represents the 13 genome-wide space of CNV variation between cases and controls. 14 15 CNV breakpoint level association was run using the epilepsy residual phenotype as a 16 quantitative variable, with significance determined through 1,000,000 permutations of 17 phenotype residual labels using PLINK v1.07 32 . An additional z-scoring correction was used 18 to efficiently estimate two-sided empirical p-values for highly significant loci. A fraction of our 19 controls were patients from an Irritable Bowl Disease (IBD) project, and therefore to rule out 20 confounding, we ran the same CNV breakpoint level association for the "IBD-controls" from 21 the Helmsley dataset (since these represent IBD cases) and used them as cases to test 22 association using the remaining controls as comparison group. IBD-related CNV breakpoints 23 with p-values <10e-3 after genome wide correction were removed from the combined 24 analysis (epilepsy cases vs all controls including IBD fraction). Association tests were 25 conducted for all CNV types, deletions, and duplications independently. CNVs spanning the 26 centromere were merged to one. Bonferroni correction for multiple testing was used to 27 identify significance threshold. Loci that surpassed genome-wide multiple testing correction 28 in either test were followed up by manual CNV quality evaluation: B-allele frequency and 1 LogR-ratio were manually investigated using perl scripts provided by PennCNV and UCSC 2 genome browser hg19 (https://genome.ucsc.edu/). 3 4 Phenotype Analysis: 5
The phenome-wide association study (PheWAS) design requires a good signal to noise ratio 6 to discover novel CNV associations. To enrich for high confidence pathogenic CNVs, we 7 tested the burden of big CNVs (>2Mb) in patients with a specific phenotype among the 8 different epilepsy phenotypes. Based on the data collected through the Epi25 consortium, 9
we were able to include 43 different phenotype categories in the PheWAS (see 10 Supplementary Methods). P-values and ORs were obtained using a Fisher's Exact Test 11 (two-sided). Multiple testing correction for 161 tests results in a significant p-value < 3.1*10 -4 . 12
We performed a meta-analysis for the association of GGE patients with big duplications (> 2 13 Mb) with febrile seizures to exclude a possible center bias using the R package "metafor" 14 (https://cran.r-project.org/web/packages/metafor/metafor.pdf). 15 16 12 Results 1 2 Elevated epilepsy type-specific CNV burden in DEE and GGE patients: 3
We applied logistic regression to investigate whether the five epilepsy phenotypes have on 4 average a greater genomic region covered (combined CNV length) by either deletions or 5 duplications. After correction for 30 tests, we found that patients with DEE and GGE showed 6 independent enrichment for total deletions of an overall length of >2Mb compared to controls 7 (DEE: OR 2.91 [1.63-4.72], p = 7.13e-5; GGE: OR 1.85 [1.27-2.58], p = 6.5e-4) ( Figure 1A) . 8 UE was the only epilepsy type with significant burden for duplications of an overall length of 9 >2Mb (OR 3.85 [2.71-5.3], p = 2.63e-15; Figure 1B Next, we measured if the CNV burden was concentrated within defined sets of genes and 5 known deletion hotspots for epilepsy (Epi) and neurodevelopmental disorders (NDD). 6
Compared to deletions identified in the controls, we found that the epilepsy hotspot list, 7 genes intolerant for truncating variants, and coding regions were enriched for patient 8 deletions (Figure 2 ). DEE and GGE patients showed a significant burden of deletions in 9 genes with pLI > 0.95 (DEE: OR 1.85 [1.3-2.53], p = 2.78e-4; GGE: OR 1.58 [1.28-1.91], p = 10 7.2e-6). Additionally, GGE patients showed an enrichment of deletions at previously 11 identified epilepsy hotspots (OR 5.21 [3.59-7.7], p = 2.01e-17) and in coding regions (OR 12 1.15 [1.07-1.24], p = 2.35e-4) but no significant enrichment of known epilepsy genes. 13 Furthermore, we detected a significant deletion enrichment in NAFE patients at previously 14 identified epilepsy deletion hotspots (OR 2.42 [1.61-3.69], p = 2.87e-5). In contrast, no 15 enrichment was observed in any genes or loci tested when duplications were considered in 16 any epilepsy phenotype ( Figure S2 
Enrichment of likely pathogenic CNVs in all epilepsy phenotypes: 1
For our next category, we evaluated the combined burden of the CNVs that are considered 2 in the literature as 'likely pathogenic' (according to ACMG, see "Methods" for selection 3 criteria) in the five studied epilepsy phenotypes. Likely pathogenic CNVs were identified in 4 6.08 % of DEEs, 7.67 % of GGEs, 5.92 % of LFEs, 4.67 % of NAFEs, and 9.27 % of UEs. 5
However, likely pathogenic CNVs were also present in 3.56 % of controls. Nevertheless, in a 6 direct comparison with the controls, we observed a significant enrichment of likely 7 pathogenic CNVs in all epilepsy phenotypes (Figure 3) . The likely pathogenic CNV effect 8 size was greatest in patients with UE (OR 2.63 [1.92-3.52], p = 4.16e-10; Figure 3 ), mainly 9 driven by large duplications ( Figure 1B) . 
Genome-wide CNV breakpoint association reveals significant loci outside of known hotspot 1 regions: 2
In total, five independent CNV loci in five epilepsy phenotypes surpassed genome-wide 3 significance; four loci have been previously reported in association with GGE 15-18 and one 4 has never been associated with epilepsy before. For three of the identified CNV loci we 5 extended the phenotypic spectrum by identifying novel epilepsy phenotype associations. In 6 line with previous results from candidate loci studies, our analysis showed that patients with 7 GGE were most significantly enriched for deletions overlapping hotspot loci on 8 chromosomes 15q13.2-q13.3 (p = 2.55e-08) and 16p13.11 (p = 3.43e-08; Figure 4A , Figure  9 S4). We identified a duplication association with GGE that was located on chromosome 9, 10 spanning 9p11.2, the centromere and 9q21.11 (p = 1.53e-07; Figure 4B , Figure S4 , S5), a 11 locus associated for the first time with an epilepsy phenotype. The DEE analysis revealed a 12 genome-wide significant duplication locus overlapping the recurrent region on chromosome 13 15q11.2-q13.1 also known as the Prader-Willi/Angelman critical region (p = 2.15e-10; Figure  14 4B). No locus was significantly enriched in the NAFE cohort. Deletions in LFE patients were 15 enriched at epilepsy hotspot 16p13.11 (p = 7.08e-08; Figure 4A ), and duplications also at 16 9p11.2-9q21.11 (p = 1.09e-10; Figure 4B ; Figure S4, S5) . Finally, the UE association 17 analyses identified significant enrichment for duplications at 1q21.1 and 9p11.2-9q21.11 (p = 18 3.30e-11; p = 3.37e-18; Figure 4B ). To verify the novel duplication region 9p11.2-9q21.11 19 significantly enriched in GGE, LFE and UE patients, we plotted the Log-R Ratio (LRR) 20 intensity and B-Allele Frequency (BAF) of the probe-levels for a subset of six patients in 21 
PheWAS analysis reveals enrichment of large CNVs (> 2Mb) in epilepsy subtypes: 1
We performed a phenome-wide association study (PheWAS) to identify an association 2 between large effect CNVs and a large number of different phenotypes. We analyzed 3 whether the CNV burden is enriched in any clinical phenotype within the five different 4 epilepsy phenotypes. After multiple testing correction for 161 applied tests, we identified two 5 significant associations. We observed a 3.25-fold enrichment of large duplications (> 2Mb) in 6 patients with GGE and febrile seizures when comparing to GGE patients without febrile 7 seizures (OR 3.25 [1.8-5.92], p = 4.07e-05; Table S2 ). Further, a 2.72-fold enrichment of 8 large duplications was detected for focal epilepsy patients with structural abnormalities 9 versus without (OR 2.72 [1.57-4.56], p = 2.33e-04; Table S2 ). An evaluation of types of 10 lesions in this group showed that pathogenic CNVs are not specific to a single lesion type 11 but found in patients with five different lesion types ( Figure S6 ). 12
Discussion 1
In this study, we identify several novel CNV-epilepsy associations using a case-control 2 approach with >18,000 individuals genotyped on the same platform and analyzed with the 3 same CNV calling, quality control, and analysis pipeline. We observe an increased burden of 4 CNVs in different epilepsy phenotypes, report novel risk loci that surpass genome-wide 5 multiple testing correction, and show that also LFE can be associated with an increased 6 CNV burden. Consistent with results from genetic studies in other neurodevelopmental 7 disorders, we show that novel risk loci lay at the ultra-rare end of the CNV frequency 8 spectrum. Thus, larger samples will be needed to identify additional risk loci at convincing 9 levels of statistical evidence 30, 31 . 10
11
CNV Burden 12
We and others have previously shown a burden of deletions overlapping genes associated 13 with neurodevelopmental processes in patients with GGE, and that the signal was 14 particularly concentrated within epilepsy hotspot loci [15] [16] [17] [18] [19] [20] [21] [22] . In the present study we were able 15 to replicate the original GGE signal with a significant enrichment for deletions in epilepsy 16 hotspots. Additionally, we observed a significant deletion burden in genes intolerant for 17 protein truncating variants in the general population, which has been suggested recently in a 18 smaller cohort of 160 generalized, 32 focal, and six unclassified epilepsy patients 39 . 19 Consistent with the well-established role of rare, large effect CNVs in the etiology of the 20 severe and early onset DEEs 13 , we identified a significant deletion enrichment covering 21 genes intolerant for truncating variants in the general population. Previous studies did not 22 find significant differences between focal epilepsy patients and controls within hotspot loci, 23 most likely due to the small sample size 22 . Here, we detect deletions overlapping epilepsy 24 hotspot regions enriched in patients with NAFE. We observed enrichment for overall large 25 duplications burden (>2Mb) for 6% of patients with UE, although we cannot exclude that a 26 subset of patients may have a severe neurodevelopmental disease phenotype. This 27 proportion is lower than in previous reports that identified that 15-20% of individuals with 28 20 unexplained neurodevelopmental disorders carry pathogenic CNVs 40 . Although epilepsy 1 associated brain lesions have mainly been associated with somatic variants, which affect the 2 mechanistic target of rapamycin (mTOR) pathway 11,12 also germline variants in DEPDC5 3 have been identified as risk factors for lesional epilepsies. Here, we show that CNVs play a 4 role in the etiology of LFE. The detected pathogenic CNVs were not specific to a single brain 5 lesion, suggesting that the CNVs confer risk to the epilepsy rather than to the lesion itself. we did not observe an enrichment of likely pathogenic CNVs in patients with these 19 comorbidities in our cohort (data not shown). Interestingly, we found an enrichment of large 20 duplications (>2Mb) in GGE patients with febrile seizures compared to GGE patients without 21 febrile seizures (Table S2, Figure S3 ). Additional comorbidities in GGE patients with CNVs 22 have been reported before (Mullen et al., 2013) we used more stringent sample inclusion criteria with a smaller fraction of patients with 14 comorbidities. This may explain why three out of seven recurrent loci were not significantly 15 enriched in our analysis. Nonetheless, we show a significant association of deletions in 16 16p13.11 with LFE. Previously, deletions of 16p13.11 were found to be enriched in 17 candidate loci studies of GGE and CECTS (Childhood epilepsy with centrotemporal spikes) 18 along with autism, intellectual disability, schizophrenia and additionally in non-lesional focal 19 epilepsies 15,18 . The signal of non-lesional focal epilepsies could have been driven by 20 misdiagnosed patients with small lesions undetectable by neuroimaging so that a lesional 21 focal epilepsy might not have been confidently ruled out in these patients. 22 23 GGE, LFE and UE were associated with a genome-wide significant duplication spanning 24 9p11.2, the centromere and 9q21.11, which has never been associated with epilepsy before. 25
Both loci harbor genes highly expressed in the brain (9p11.2: FAM27E3; 9q21.11: e.g. 26 PIP5K1B, APBA1). However, regions around the centromere of chromosome 9 (9p12, 9q13-27 q21.12) have also been repeatedly found and described as euchromatic cytogenetically 28 22 visible copy number variations (CG-CNVs) 51,52 in close proximity to the regions we identified. 1 So far, these regions have been reported to be prone to benign CNVs and have not been 2 associated with any phenotypic consequence before. Further large-scale studies will help to 3 confirm this signal (see also Figure S5 for examples of CNVs at this region). CNVs covering 4 the identified region and additional genomic regions have been associated with several 5 severe syndromes. Among patients with 9p duplication syndrome characterized by growth 6 and developmental delay 53 , a patient duplication covering 9p11.2 was described 54 . Typical 7 characteristics for the 9p duplication syndrome include further microbrachcephaly, atypical 8 face morphology, and delayed bone age 55-57 . Wilson and colleagues proposed that the 9 spectrum of clinical severity in the 9p duplication syndrome roughly correlates with the extent 10 of trisomic chromosome material (Wilson et al., 1985) , which could explain a milder 11 phenotype for our LFE and UE patients with duplication of loci 9p11.2 and not the entire 12 chromosome arm. The 9p11.2-9q21.11 duplication is enriched in epilepsy patients similar to 13 the 15q.11.2 deletion, as it is present in the general population but clearly enriched in people 14 with various neuropsychiatric disorders and idiopathic generalized epilepsies implicating that 15 this CNV acts as a risk factor instead of a large effect variant. 16 17 18
Study limitations 19
It is important to note that CNV breakpoints in the current study are estimated from 20 genotyped SNPs around the true breakpoint, and these breakpoint estimates are limited by 21 the resolution of the genotyping platform. Last, we recognize that especially small structural 22 variants are not detectable with current genotyping platforms 58 . New technologies for whole-23 genome sequencing will ultimately enable the assessment of the contribution of a wider 24 array of rare variants, including balanced re-arrangements, small CNVs 59 and short tandem 25 repeats 60 . 26 27 Summary 28 23 Large-scale collaborations in epilepsy genetics have greatly advanced discovery through 1 genome-wide association studies. Here, we have extended this framework to rare CNVs in 2 five different epilepsy phenotypes including stringent ancestry and data quality control 3 criteria, after generating the data under the same genotype array and calling pipeline for 4 each subject. Our results help to refine the list of promising candidate CNVs associated with 5 specific epilepsy types and extend the phenotypic spectrum for identified loci. We are 6 confident that the application of this framework to even larger datasets has the potential to 7 advance the discovery of loci and identification of the relevant genes and functional 8 elements. 9
